RT Journal Article
SR Electronic
T1 Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.06.21254963
DO 10.1101/2021.04.06.21254963
A1 Sattler, Arne
A1 Schrezenmeier, Eva
A1 Weber, Ulrike
A1 Potekhin, Alexander
A1 Bachmann, Friederike
A1 Budde, Klemens
A1 Storz, Elena
A1 Proß, Vanessa
A1 Bergmann, Yasmin
A1 Thole, Linda
A1 Tizian, Caroline
A1 Hölsken, Oliver
A1 Diefenbach, Andreas
A1 Schrezenmeier, Hubert
A1 Jahrsdörfer, Bernd
A1 Zemojtel, Tomasz
A1 Jechow, Katharina
A1 Conrad, Christian
A1 Lukassen, Sören
A1 Stauch, Diana
A1 Lachmann, Nils
A1 Choi, Mira
A1 Halleck, Fabian
A1 Kotsch, Katja
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.06.21254963.abstract
AB Novel mRNA-based vaccines have been proven powerful tools to combat the global pandemic caused by SARS-CoV2 with BNT162b2 efficiently protecting individuals from COVID-19 across a broad age range. Still, it remains largely unknown how renal insufficiency and immunosuppressive medication affect development of vaccine induced immunity. We therefore comprehensively analyzed humoral and cellular responses in kidney transplant recipients after prime-boost vaccination with BNT162b2. As opposed to all healthy vaccinees and the majority of hemodialysis patients, only 4/39 and 1/39 transplanted individuals showed IgA and IgG seroconversion at day 8±1 after booster immunization with minor changes until day 23±5, respectively. Although most transplanted patients mounted spike-specific T helper cell responses, frequencies were significantly reduced compared to controls and dialysis patients, accompanied by a broad impairment in effector cytokine production, memory differentiation and activation-related signatures. Spike-specific CD8+ T cell responses were less abundant than their CD4+ counterparts in healthy controls and hemodialysis patients and almost undetectable in transplant patients. Signs of alloreactivity promoted by BNT162b2 were not documented within the observation period. In summary, our data strongly suggest revised vaccination approaches in immunosuppressed patients, including individual immune monitoring for protection of this vulnerable group at risk to develop severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank the Charite Universitaetsmedizin Benjamin Franklin Flow Cytometry Core Facility (M. Fernandes and A. Branco) supported by DFG Instrument Grants (INST 335/597-1 FUGG, INST 335/777-1 FUGG). The study was supported by a grant from the Sonnenfeldstiftung, Berlin, Germany to Arne Sattler and Katja Kotsch and DFG grants (KO 2270/7-1, KO-2270/4-1) to Katja Kotsch. Eva Schrezenmeier is participant in the BIH-Charite Clinician Scientist Program funded by the Charite-Universitaetsmedizin Berlin and the Berlin Institute of Health and received further support (BCOVIT, 01KI20161) from the Federal Ministry of Education and Research (BMBF). Oliver Hoelsken was supported by the Heidelberg Bioscience International Graduate School MD/PhD program, Heidelberg University, Germany. Hubert Schrezenmeier received funding from the Ministry for Science, Research and Arts of Baden-Wuerttemberg, Germany and the European Commission (HORIZON2020 Project SUPPORT-E, no. 101015756). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of the Charite-Universitaetsmedizin Berlin (EA4/188/20), Universitaetsmedizin Greifswald (BB 019/21), and Sachsen-Anhalt (EA7/21) and carried out in compliance with its guidelines. All participants gave written informed consent in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon reasonable request.